Form 4 for DGX Quest Diagnostics
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-04 · accession 0001022079-25-000086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-05 | 2025-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $173.74 | +5,317 | 11.3K | +89% | +$923.8K | |
| 2025-03-05 | 2025-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $173.74 | -1,823 | 9,477 | -16% | -$316.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | A | A | 5,317 | $173.74 | 11,300 | D | — | — | (F1) Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). |
| 2 | Common | Common Stock | 2025-03-04 | F | D | 1,823 | $173.74 | 9,477 | D | — | — | (F2) Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. |